Vitruvias Therapeutics has recalled one lot of its 30 mg thyroid tablets nationwide after testing found the medicine could be more potent than intended. Patients using the product should check their prescription packaging carefully, but should not stop taking the medicine without first speaking with a healthcare provider.
The voluntary recall involves Thyroid Tablets, USP 30 mg, lot number 504950. The U.S. Food and Drug Administration listed the recall on August 24, 2026, citing the potential for the product to be superpotent.
Which Vitruvias thyroid tablets are recalled?
The affected medicine is Thyroid Tablets, USP 30 mg. Patients should look for NDC 69680-166-00, lot number 504950 and an expiration date of September 30, 2026.
The affected lot was distributed nationwide to Vitruvias Therapeutics’ direct accounts between January 31 and September 30, 2025. According to the recall information, 3,655 units were released and 1,955 units were sold.
This is a specific-lot recall, not a recall of every thyroid medicine. Checking the lot number and other identifiers is therefore important. The same approach applies to other targeted drug recalls, including a recent cetirizine allergy tablet recall involving four affected lots.
Why was lot 504950 recalled?
Testing confirmed that tablets from the affected lot could potentially be superpotent. This means a patient could receive greater thyroid hormone activity than intended even while following the prescribed dose.
Thyroid Tablets, USP are a natural preparation derived from porcine thyroid glands and contain the thyroid hormones levothyroxine and liothyronine. They are used to treat hypothyroidism, commonly called an underactive thyroid.
Potency is particularly important with thyroid treatment because the dose is intended to maintain appropriate hormone levels. This recall concerns the strength of the medicine rather than contamination or foreign material.
What symptoms can superpotent thyroid tablets cause?
Excessive thyroid hormone exposure can cause hyperthyroidism, or an overactive thyroid. Potential symptoms identified in the recall include weight loss, heat intolerance, fatigue, nervousness, muscle weakness and hypertension.
More serious effects can include chest pain, rapid heart rate and heart rhythm disturbances. Anyone experiencing concerning symptoms while taking the affected medicine should contact a healthcare professional.
Drug recalls can involve very different manufacturing or quality problems. In another recent case, more than 2.5 million bottles of prescription eye drops were recalled over a potential foreign substance, rather than a potency concern.
Who may face a greater risk?
The FDA identifies older adults, pregnant women and infants as groups at greater risk, particularly if excessive thyroid hormone exposure continues for an extended period.
In older adults, excessive thyroid hormone can be associated with adverse cardiac outcomes. Overtreatment during pregnancy has been associated with premature delivery and low birth weight, while excessive treatment in infants may negatively affect normal growth and development.
Vitruvias Therapeutics said it had not received reports of adverse events associated with the recalled tablets at the time of the announcement. The recall was initiated because of the product-quality finding rather than a reported cluster of illnesses.
What is Vitruvias Therapeutics doing about the recall?
The company is notifying wholesalers by email and phone to stop distributing the affected product and is arranging for destruction of recalled inventory.
Patients who discover that they have lot 504950 should not simply discontinue treatment. Hypothyroidism requires appropriate hormone replacement, and a healthcare provider can advise whether a replacement prescription or other action is needed.
FDA Recalls 11,460 Bottles of Blood Pressure Medication Over Effectiveness Concerns
FDA Recalls Nearly 16,000 Blood Pressure Drug Bottles Nationwide
What should patients with lot 504950 do?
Patients taking the recalled tablets should not discontinue their medication without first contacting their healthcare provider. A doctor or pharmacist can help confirm whether the prescription is affected and provide guidance about replacement treatment.
For verification, patients should compare four details on their medicine: 30 mg strength, NDC 69680-166-00, lot 504950 and the September 30, 2026 expiration date. The FDA’s official drug recall database can be used to check current federal recall information.
Consumers with questions can contact Vitruvias Therapeutics at safety@vitruvias.com or (256) 239-9373, Monday through Friday from 9 a.m. to 5 p.m. Central Time. Anyone experiencing an adverse reaction or other health problem should contact a healthcare professional.
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
